Currently out of the existing stock ratings of Kyle Mikson, 111 are a BUY (90.98%), 11 are a HOLD (9.02%).

Kyle Mikson

Work Performance Price Targets & Ratings Chart

Analyst Kyle Mikson, currently employed at CANACCORD, carries an average stock price target met ratio of 25.1% that have a potential upside of 21.6% achieved within 77 days.

Kyle Mikson’s has documented 239 price targets and ratings displayed on 17 stocks. The coverage is on Healthcare, Basic Materials sectors.

Most recent stock forecast was given on AKYA, Akoya Biosciences at 15-Nov-2024.

Wall Street Analyst Kyle Mikson

Analyst best performing recommendations are on TTOO (T2 BIOSYSTMS).
The best stock recommendation documented was for TTOO (T2 BIOSYSTMS) at 4/29/2024. The price target of $3 was fulfilled within 1 day with a profit of $0.16 (5.63%) receiving and performance score of 56.34.

Average potential price target upside

of $42.01 (69.85%) on NTRA (NATERA).
of $7.48 (61.06%) on XGN (EXAGEN).
of $6.28 (9.23%) on EXAS (EXACT SCIENCES).

BDSX Biodesix ILMN Illumina LUCD Lucid Diagnostics NTRA Natera PACB Pacific Biosciences of California QSI QuantumSi XGN Exagen CSTL Castle Biosciences EXAS EXACT Sciences GH Guardant Health NSTG NanoString Technologies QTRX Quanterix Corp TTOO T2 Biosystms SLGC Somalogic TX Ternium SA ADR AKYA Akoya Biosciences TXG 10X Genomics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Kyle Mikson (CANACCORD)